 |
 |
|
|
|  PubMed
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 July 2000 | Volume 133 Issue 1 | Pages 35-39
Background: Antiretroviral regimens containing HIV protease inhibitors suppress viremia in HIV-infected patients, but the durability of this effect is not known.
Objective: To describe the 3-year follow-up of patients randomly assigned to receive indinavir, zidovudine, and lamivudine in an ongoing clinical trial.
Design: Open-label extension of a randomized, double-blind study.
Setting: Four clinical research units.
Patients: 33 HIV-infected, zidovudine-experienced patients with serum HIV RNA levels of at least 20 000 copies/mL and CD4 counts ranging from 50 to 400 cells/mm3.
Intervention: Indinavir, zidovudine, and lamivudine.
Measurements: Safety assessments, HIV RNA levels, CD4 cell counts, and genotypic analyses.
Results: After 3 years of follow-up, 21 of 31 contributing patients (68% [95% CI, 49% to 83%]) had serum viral load levels less than 500 copies/mL. Twenty of 31 (65% [CI, 45% to 80%]) had levels less than 50 copies/mL. The median increase in CD4 count from baseline was 230 cells/mm3 (interquartile range, 150 to 316 cells/mm3). Nephrolithiasis occurred in 12 of 33 patients (36%).
Conclusion: A three-drug regimen of indinavir, zidovudine, and lamivudine suppressed viremia in two thirds of patients for at least 3 years.
Author and Article Information
From Weill Medical College of Cornell University and New York University School of Medicine, New York, New York; University of Pittsburgh School of Medicine and Pittsburgh Veterans Affairs Medical Center, Pittsburgh, Pennsylvania; University of California and San Diego Veterans Affairs Medical Center, San Diego, California; University of North Carolina School of Medicine, Chapel Hill, North Carolina; and Merck Research Laboratories, West Point, Pennsylvania.
Presented in part at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, Illinois, 31 January to 4 February 1999.
Disclaimer: Merck & Co., Inc., has made research grants to Cornell University; University of North Carolina; University of California, San Diego; and New York University. Drs. Gulick, Eron, and Richman are ad hoc consultants for Merck. Dr. Eron is an ad hoc consultant for Glaxo Wellcome. Drs. Gulick and Eron have received honoraria for lectures from Merck and Glaxo Wellcome. Drs. Meibohm, Condra, Emini, Chodakewitz, and Isaacs and Ms. Jonas are employees of Merck and own stocks and stock options.
Acknowledgments: The authors thank the patient volunteers and the study coordinators: Candida Talabucon, RN; Richard Hutt, RN; Nancy Mantz, BSN; Carl Garrubba, PA; Kathy Nuffer, RN; Jackie Stewart, RN; and Janet Kozel, PA. They thank Malathi Shivaprakash, MS; Kalpana Bakshi, MS; Robert M. Danovich, PhD; and Donald J. Graham, BS, for technical virologic support and Glaxo Wellcome for providing zidovudine and lamivudine.
Grant Support: By the National Institutes of Health (AI 36214 [University of California, San Diego, Center for AIDS Research] and P30-HD37260 [University of North Carolina Center for AIDS Research]) and by individual grants from Merck Research Laboratories, West Point, Pennsylvania.
Requests for Single Reprints: Roy M. Gulick, MD, MPH, Cornell Clinical Trials Unit, 525 East 68th Street, Box 566, New York, NY 10021; e-mail, rgulick{at}med.cornell.edu.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. Gulick: Cornell Clinical Trials Unit, 525 East 68th Street, Box 566, New York, NY 10021.
Drs. Mellors and McMahon: Graduate School of Public Health, University of Public Health, University of Pittsburgh Medical Center, 603 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261.
Dr. Havlir: HIV Investigational Drug Treatment Center, University of California, San Diego, 2760 Fifth Avenue, Suite 300, San Diego, CA 92103.
Dr. Eron: Division of Infectious Diseases, University of North Carolina at Chapel Hill, 547 Burnett-Womack Building, CB 7030, Chapel Hill, NC 27599.
Drs. Meibohm, Condra, Emini, Chodakewitz, and Isaacs and Ms. Jonas: Merck & Co., Inc., Box 4, BL 3-4, West Point, PA 19486.
Drs. Valentine and Gonzalez: New York University School of Medicine, 550 First Avenue, CD 517, New York, NY 10016.
Dr. Richman: Departments of Pathology and Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093.
Author Contributions: Conception and design: R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, L. Jonas, E.A. Emini, J.A. Chodakewitz, R. Isaacs, D.D. Richman.
Analysis and interpretation of the data: R.M. Gulick, J.W. Mellors, D. Havlir, A. Meibohm, J.H. Condra, C. Gonzalez, E.A. Emini, R. Isaacs, D.D. Richman.
Drafting of the article: R.M. Gulick, J.W. Mellors, J.J. Eron, A. Meibohm, J.H. Condra, C. Gonzalez, R. Isaacs, D.D. Richman.
Critical revision of the article for important intellectual content: R.M. Gulick, J.W. Mellors, J.J. Eron, A. Meibohm, J.H. Condra, F.T. Valentine, D. McMahon, C. Gonzalez, J.A. Chodakewitz, R. Isaacs, D.D. Richman.
Final approval of the article: R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, A. Meibohm, J.H. Condra, F.T. Valentine, D. McMahon, E.A. Emini, J.A. Chodakewitz, R. Isaacs, D.D. Richman.
Provision of study materials or patients: R.M. Gulick, J.W. Mellors, D. Havlir, J.J. Eron, F.T. Valentine, D. McMahon, C. Gonzalez, L. Jonas, D.D. Richman.
Statistical expertise: A. Meibohm.
Administrative, technical, or logistic support: L. Jonas, R. Isaacs.
Collection and assembly of data: R.M. Gulick, J.W. Mellors, D. Havlir, J.H. Condra, C. Gonzales, L. Jonas, R. Isaacs. BRIEF COMMUNICATION
3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  G. D. Sanders, A. M. Bayoumi, M. Holodniy, and D. K. Owens Cost-Effectiveness of HIV Screening in Patients Older than 55 Years of Age Ann Intern Med, June 17, 2008; 148(12): 889 - 903. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lambert-Niclot, P. Flandre, A. Canestri, G. Peytavin, C. Blanc, R. Agher, C. Soulie, M. Wirden, C. Katlama, V. Calvez, et al. Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir Antimicrob. Agents Chemother., February 1, 2008; 52(2): 491 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Atta, J. E. Gallant, M. H. Rahman, N. Nagajothi, L. C. Racusen, P. J. Scheel, and D. M. Fine Antiretroviral therapy in the treatment of HIV-associated nephropathy Nephrol. Dial. Transplant., October 1, 2006; 21(10): 2809 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. De Meyer, H. Azijn, D. Surleraux, D. Jochmans, A. Tahri, R. Pauwels, P. Wigerinck, and M.-P. de Bethune TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2314 - 2321. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Sanders, A. M. Bayoumi, V. Sundaram, S. P. Bilir, C. P. Neukermans, C. E. Rydzak, L. R. Douglass, L. C. Lazzeroni, M. Holodniy, and D. K. Owens Cost-Effectiveness of Screening for HIV in the Era of Highly Active Antiretroviral Therapy N. Engl. J. Med., February 10, 2005; 352(6): 570 - 585. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. S. Justesen, N. A. Klitgaard, K. Brosen, and C. Pedersen Dose-dependent pharmacokinetics of delavirdine in combination with amprenavir in healthy volunteers J. Antimicrob. Chemother., July 1, 2004; 54(1): 206 - 210. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Bergshoeff, P. L. A. Fraaij, A. M. C. van Rossum, G. Verweel, L. H. Wynne, G. A. Winchell, R. Y. Leavitt, B.-Y. T. Nguyen, R. de Groot, and D. M. Burger Pharmacokinetics of Indinavir Combined with Low-Dose Ritonavir in Human Immunodeficiency Virus Type 1-Infected Children Antimicrob. Agents Chemother., May 1, 2004; 48(5): 1904 - 1907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. S. Furfine, C. T. Baker, M. R. Hale, D. J. Reynolds, J. A. Salisbury, A. D. Searle, S. D. Studenberg, D. Todd, R. D. Tung, and A. Spaltenstein Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir Antimicrob. Agents Chemother., March 1, 2004; 48(3): 791 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. de Mendoza, E. Paxinos, P. Barreiro, N. Camino, M. Nunez, and V. Soriano Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations J. Clin. Microbiol., February 1, 2004; 42(2): 862 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Robbins, V. De Gruttola, R. W. Shafer, L. M. Smeaton, S. W. Snyder, C. Pettinelli, M. P. Dube, M. A. Fischl, R. B. Pollard, R. Delapenha, et al. Comparison of Sequential Three-Drug Regimens as Initial Therapy for HIV-1 Infection N. Engl. J. Med., December 11, 2003; 349(24): 2293 - 2303. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Havlir, M. C. Strain, M. Clerici, C. Ignacio, D. Trabattoni, P. Ferrante, and J. K. Wong Productive Infection Maintains a Dynamic Steady State of Residual Viremia in Human Immunodeficiency Virus Type 1-Infected Persons Treated with Suppressive Antiretroviral Therapy for Five Years J. Virol., October 15, 2003; 77(20): 11212 - 11219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. A. Pilon, J. J. Lum, J. Sanchez-Dardon, B. N. Phenix, R. Douglas, and A. D. Badley Induction of Apoptosis by a Nonnucleoside Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor Antimicrob. Agents Chemother., August 1, 2002; 46(8): 2687 - 2691. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. C. van Rossum, J. P. Dieleman, P. L. A. Fraaij, K. Cransberg, N. G. Hartwig, D. M. Burger, I. C. Gyssens, and R. de Groot Persistent Sterile Leukocyturia Is Associated With Impaired Renal Function in Human Immunodeficiency Virus Type 1-Infected Children Treated With Indinavir Pediatrics, August 1, 2002; 110(2): e19 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Maguire, R. Guinea, P. Griffin, S. Macmanus, R. C. Elston, J. Wolfram, N. Richards, M. H. Hanlon, D. J. T. Porter, T. Wrin, et al. Changes in Human Immunodeficiency Virus Type 1 Gag at Positions L449 and P453 Are Linked to I50V Protease Mutants In Vivo and Cause Reduction of Sensitivity to Amprenavir and Improved Viral Fitness In Vitro J. Virol., June 27, 2002; 76(15): 7398 - 7406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Joly, P. Flandre, V. Meiffredy, F. Brun-Vezinet, J.-A. Gastaut, C. Goujard, G. Remy, D. Descamps, A. Ruffault, A. Certain, et al. Efficacy of Zidovudine Compared to Stavudine, Both in Combination with Lamivudine and Indinavir, in Human Immunodeficiency Virus-Infected Nucleoside-Experienced Patients with No Prior Exposure to Lamivudine, Stavudine, or Protease Inhibitors (Novavir Trial) Antimicrob. Agents Chemother., June 1, 2002; 46(6): 1906 - 1913. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. J. Goldie, J. E. Kaplan, E. Losina, M. C. Weinstein, A. D. Paltiel, G. R. Seage III, D. E. Craven, A. D. Kimmel, H. Zhang, C. J. Cohen, et al. Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines Arch Intern Med, April 22, 2002; 162(8): 921 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. E. van Praag, E. C. M. van Weert, R. P. G van Heeswijk, X.-J. Zhou, J.-P. Sommadossi, S. Jurriaans, J. M. A. Lange, R. M. W. Hoetelmans, and J. M. Prins Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy Antimicrob. Agents Chemother., March 1, 2002; 46(3): 896 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Zhao, X.-L. Huang, P. Gupta, L. Borowski, Z. Fan, S. C. Watkins, E. K. Thomas, and C. R. Rinaldo Jr. Induction of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ and CD4+ T-Cell Reactivity by Dendritic Cells Loaded with HIV-1 X4-Infected Apoptotic Cells J. Virol., February 22, 2002; 76(6): 3007 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Freedberg, E. Losina, M. C. Weinstein, A. D. Paltiel, C. J. Cohen, G. R. Seage, D. E. Craven, H. Zhang, A. D. Kimmel, and S. J. Goldie The Cost Effectiveness of Combination Antiretroviral Therapy for HIV Disease N. Engl. J. Med., March 15, 2001; 344(11): 824 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Dworkin and P.-C. T. Wan Indinavir, Zidovudine, Lamivudine: 3-Year Follow-up Ann Intern Med, January 16, 2001; 134(2): 165 - 165. [Full Text] [PDF]
|
|
|
|
 |
|
 J. O. Kahn, D. W. Cherng, K. Mayer, H. Murray, S. Lagakos, and for the 806 Investigator Team Evaluation of HIV-1 Immunogen, an Immunologic Modifier, Administered to Patients Infected With HIV Having 300 to 549 x 106/L CD4 Cell Counts: A Randomized Controlled Trial JAMA, November 1, 2000; 284(17): 2193 - 2202. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Gulick Assessing the Benefits of Antiretroviral Therapy Ann Intern Med, September 19, 2000; 133(6): 471 - 473. [Full Text] [PDF]
|
|
|
|
 |
|
 Adherence, Treatment Duration, and HIV Suppression Journal Watch (General), August 4, 2000; 2000(804): 2 - 2. [Full Text]
|
|
|
|
 |
|
 S. A. Stranford, J. C. Ong, B. Martinez-Marino, M. Busch, F. M. Hecht, J. Kahn, and J. A. Levy Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection PNAS, January 16, 2001; 98(2): 597 - 602. [Abstract] [Full Text] [PDF]
|
|
